PENILAIAN RESPON KLINIS DAN KADAR SCC KEMOTERAPI
KOMBINASI PACLITAXEL CARBOPLATIN
PADA KARSINOMA SERVIKS STADIUM LANJUT
CLINICAL ASSESSMENT RESPONSE AND LEVELS SCC OF
COMBINATION CHEMOTHERAPHY PACLITAXEL CARBOPLATIN FOR
ADVANCED STAGE CERVICAL CARCINOMA
Ainun J.Palinrungi, Syahrul Rauf, Efendi Lukas
Bagian Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Hasanuddin
Alamat Korespondensi :
Ainun J. Palinrungi
Bagian Obstetri dan Ginekologi
Fakultas Kedokteran
Universitas Hasanuddin
Makassar
HP: (0411)2430347, 081355519973
Email : ainun.jamila@gmail.com
Abstrak
Respon Klinis Dan Kadar SCC Kemoterapi Kombinasi Paclitaxel Carboplatin pada Karsinoma Serviks Stadium Lanjut sampai saat ini belum banyak diteliti. Penelitian ini bertujuan Untuk menilai respon klinis dan kadar antigen SCC sebelum dan sesudah kemoterapi kombinasi Paclitaxel-Carboplatin pada karsinoma serviks stadium lanjut. Penelitian ini dilaksanakan dengan kohort prospektif mulai 1 Maret 2013 sampai 31 Agustus 2013 pada beberapa rumah sakit pendidikan Bagian Obstetri dan Ginekologi Fakultas Kedokteran Universitas Hasanuddin Makassar, antara lain: RSUP. Dr. Wahidin Sudirohusodo, RS. Pelamonia, RSI. Faisal, RSU. Labuang Baji, RSU. Bhayangkara, RSU. Stella Maris, RS. Hikmah, RS.Haji dan RSUD Gowa. Jumlah sampel penelitian 30 orang. Tes Abnormalitas dilakukan dimana data diuji dengan Shapirowilk test dan didapatkan data yang berdistribusi tidak normal.Analisa data perbandingan antara kadar antigen SCC dalam serum darah sebelum dan sesudah kemoterapi Paclitaxel Carboplatin diuji perbedaannya dengan uji Wilcoxon test, perubahan kadar antigen SCC dalam serum darah sebelum dan sesudah kemoterapi Paclitaxel Carboplatin berdasarkan respon klinis diuji memakai uji Mann Whitney. Hasil penelitian menunjukkan terdapat perbedaan kadar antigen SCC dan respon klinis yang berbeda pada karsinoma serviks stadium lanjut sebelum dan sesudah pemberian kemoterapi kombinasi Paclitaxel-Carboplatin nilai p = 0,000(p<0.05). Simpulan pada penelitian ini didapatkan respon klinis dan penurunan kadar SCC pada pemberian kemoterapi kombinasi Paclitaxel-Carboplatin.
Kata kunci : Paclitaxel-Carboplatin, SCC, karsinoma serviks.
Abstract
The Clinical response of Combination Chemotherapy SCC carboplatin Paclitaxel in Advanced Stage Cervical Carcinoma still not well understood . This study aimed to assess the clinical response and SCC antigen levels before and after combination chemotherapy ofPaclitaxel - Carboplatin in advanced cervical carcinoma . This study was conducted with a prospective cohort starting March 1, 2013 until August 31, 2013 at a teaching hospital Department of Obstetrics and Gynecology, Faculty of Medicine, Hasanuddin University, Makassar ,include : Dr. . Wahidin Sudirohusodo , RS . Pelamonia , RSI . Faisal , RSU . Labuang Baji , RSU . Bayangkara, RS. Stella Maris , RS . Hikmah ,RS.Haji , and RS Gowa . Total samplse are 30 people . Abnormality test is performed which testedusing Shapirowilk test thus the data obtained not normal distributed. The analysis of comparative data between SCC antigen levels in blood serum before and after chemotherapy with Paclitaxel Carboplatin tested using Wilcoxon test , changes in levels of SCC antigen in the blood serum before and after chemotherapy Paclitaxel carboplatin based on clinical response were tested using the Mann Whitney test . The results showed there is a differencein SCC antigen levels and clinical response in advanced cervical carcinoma before and after chemotherapy using combination of Paclitaxel - Carboplatin value of p = 0.000 ( p < 0.05), . The conclusions is there is a clinical response and decreased levels of SCC in combination chemotherapy of Paclitaxel - Carboplatin Keywords : Paclitaxel - Carboplatin , SCC , cervical carcinoma .